This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of +37.04% and +4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -41.18% and 28.14%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 4.20% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -35.71% and 12.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 25.30% and 293.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?
by Zacks Equity Research
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -8.33% and 6.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 51.85% and 6.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 72.73% and 59.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 16th
by Zacks Equity Research
ALB, AAL and AQST have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2024.
New Strong Sell Stocks for July 11th
by Zacks Equity Research
AQST, CENTA and RAMP have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2024.
5 Small Drug Stocks to Buy From a Recovering Industry
by Kinjel Shah
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -88.89% and 1.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
by Zacks Equity Research
Verrica Pharmaceuticals (VRCA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $4.38, denoting no change from the preceding trading day.